BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 12094328)

  • 1. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
    Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
    Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
    Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
    Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
    Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.
    Jekimovs CR; Chen X; Arnold J; Gatei M; Richard DJ; Spurdle AB; Khanna KK; Chenevix-Trench G;
    Br J Cancer; 2005 Feb; 92(4):784-90. PubMed ID: 15700044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
    Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
    Rajkumar T; Soumittra N; Nancy NK; Swaminathan R; Sridevi V; Shanta V
    Asian Pac J Cancer Prev; 2003; 4(3):203-8. PubMed ID: 14507240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.
    Rashid MU; Jakubowska A; Justenhoven C; Harth V; Pesch B; Baisch C; Pierl CB; Brüning T; Ko Y; Benner A; Wichmann HE; Brauch H; Hamann U;
    Eur J Cancer; 2005 Dec; 41(18):2896-903. PubMed ID: 16239104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited relevance of the CHEK2 gene in hereditary breast cancer.
    Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
    Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
    Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
    Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma.
    Lipton L; Fleischmann C; Sieber OM; Thomas HJ; Hodgson SV; Tomlinson IP; Houlston RS
    Cancer Lett; 2003 Oct; 200(2):149-52. PubMed ID: 14568168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.
    Meijers-Heijboer H; Wijnen J; Vasen H; Wasielewski M; Wagner A; Hollestelle A; Elstrodt F; van den Bos R; de Snoo A; Fat GT; Brekelmans C; Jagmohan S; Franken P; Verkuijlen P; van den Ouweland A; Chapman P; Tops C; Möslein G; Burn J; Lynch H; Klijn J; Fodde R; Schutte M
    Am J Hum Genet; 2003 May; 72(5):1308-14. PubMed ID: 12690581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.